Before you build an AI strategy around your lab’s data, read the contracts.

Generating the data does not automatically give you every right to use it. And “we have a business associate agreement” does not settle the question.

Bradley Bostic joins McDonald Hopkins attorneys Emily Johnson, Christal Contini, and Elizabeth “Liz” Sullivan for a candid conversation about the decisions that can create—or compromise—a lab’s long-term value.

Recorded at Executive War College in New Orleans, this episode connects data rights, reimbursement pressure, and lab acquisitions to the questions healthcare leaders need to ask before committing.

THREE TAKEAWAYS:

• Understand your data rights before building the business case. The guests explain why contractual permissions around de-identification, aggregation, and reuse deserve closer attention.

• Examine the billing model behind the innovation. Digital pathology and genetic testing expose the gap between what technology makes possible and what reimbursement rules support.

• Know what you are giving up before selling the lab. Outreach revenue, strategic flexibility, and restrictions on reentering the market all belong in the decision—not just the purchase price.

Plus: why “other labs are doing it” is a poor defense, and how yesterday’s compliance decisions can become tomorrow’s acquisition problems.

What is the most overlooked asset in a health system’s lab—and does leadership understand its value?

Watch the conversation and share your perspective below.

Subscribe to Boombostic Health for conversations with the leaders shaping diagnostics and healthcare.

#Diagnostics #HealthcareData #BoombosticHealth